Actively Recruiting
[18F]FES PET/.CT in Uterine Cancer
Led by Abramson Cancer Center at Penn Medicine · Updated on 2025-05-08
30
Participants Needed
1
Research Sites
173 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. \[18F\]fluoroestradiol (FES) PET/CT imaging will be used to evaluate estrogen receptor (ER) activity in areas of disease known by standard of care imaging (e.g. CT, MRI, Bone Scan, FDG PET/CT, ultrasound) or clinical exam. For patients starting a new line of therapy, imaging will occur prior to starting new therapy. For patients who completed an initial scan and are starting new therapy, some patients may also undergo a second FES PET/CT scan at the time of suspected progression of disease to compare for changes in FES uptake measures (prior to initiation of next line therapy). The selection of therapy will be made by a treating physician and will not be affected by participation in this imaging study. Results of the FES PET/CT scan may be shared with the treating physician or subject by request but will not be used to make clinical decisions about treatment.
CONDITIONS
Official Title
[18F]FES PET/.CT in Uterine Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants will be 60 18 years of age
- Have recurrent, metastatic, or intact non-operated uterine cancer confirmed by biopsy or standard imaging
- Have at least one lesion outside the liver detected by standard imaging
- Be informed about the investigational nature of the study and willing to provide written consent
- Have completed an 8-week or 28-week washout period if recently on tamoxifen or fulvestrant, respectively
You will not qualify if you...
- Females who are pregnant at screening
- Unable to tolerate imaging procedures as determined by the investigator or treating physician
- Have any medical condition or illness that could compromise safety or successful participation as assessed by a physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
E
Erin o Schubert
CONTACT
S
Shannon Long
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here